|
|
|
| Expression of myeloid-derived suppressor cells in targeted phosphatase of regeneratiing liver-3 mouse breast tumor gene immunity |
| LYU Juan1 HUANG Hao2 ZHAO Yantian1 |
1.Department of Clinical Laboratory, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China;
2.Key Laboratory of Carcinogenesis and Translational Research, Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing 100142, China |
|
|
|
Abstract Objective To observe the expression of myeloid suppressor cells (MDSC) in targeted phosphatase of regeneratiing liver-3 (PRL-3) mouse breast tumor gene immunity, and to explore the relationship between the number of MDSC and tumor growth. Methods Forty female BALB/c mice were divided into five groups (eight groups): no-load control group (pVAX1 [-] group), adjuvanted PRL-3 group (K-PRL3 group), adjuvanted PRL-3 fusion protein group (K-T-PRL3 group and K-PRL3-MT group), and MDSC control antibody deletion group (K-T-PRL3+Ab control group and K-PRL3-MT+Ab control group). In the MDSC specific antibody deletion group (K-T-PRL3+ GR-1AB group and K-PRL3-MT+ GR-1 Ab group), immunophenotypes CD45, GR-1 and CD11b were detected by flow cytometry to analyze the expression levels of MDSC in peripheral blood, tumor and spleen of each immune group, and the correlation between MDSC and tumor growth was observed. Results On the 28th day after tumor-bearing, the tumor volume of K-PRL3 group, K-T-PRL3 group and K-PRL3-MT group was all smaller than pVAX1 (-) group, with statistically significant differences (all P < 0.05).There was no significant difference in tumor volume between the K-PRL3-mt group and K-T-PRL3 group and K-PRL3 group (P > 0.05). The expression of MDSC in peripheral blood or tumor tissues of the adjuvant -PRL-3 fusion protein group was higher than that of the K-PRL3 group, and the difference was statistically significant (P ＜ 0.05). There was no significant difference in tumor volume between MDSC specific antibody deletion group (K-T-PRL3 + GR-1 Ab group and K-PRL3-mL + GR-1 Ab group) and MDSC Control group (K-T-PRL3 +Ab control group and K-PRL3-MT +Ab control group) (P ＞ 0.05). The tumor volume of the MDSC specific antibody deletion group and the MDSC control antibody deletion group were all larger than those of the adjuvant-free PRL-3 group and the adjuvant-PRL-3 fusion protein group, with statistically significant differences (P ＜ 0.01). The expression of MDSC in spleen and peripheral blood of the MDSC specific antibody deletion group was lower than that of the control antibody deletion group, while the difference between the expression of MDSC in tumor tissues and that of the MDSC control antibody deletion group was not statistically significant (P ＞ 0.05), and was greater than that of the adyuvanted-PRL-3 fusion protein group, with statistically significant difference (P ＜ 0.01). Conclusion MDSC in tumor tissues in the adjuvant-PRL-3 fusion protein group is correlated with tumor growth in breast tumor by DNA vaccination against PRL-3, providing a theoretical basis for further optimization of anti-tumor immunotherapy against PRL-3 and research on the related effects of MDSC.
|
|
|
|
|
|
[1] Medzhitov R，Shevach EM，Trinchieri G，et al. Highlights of 10 years of immunology in Nature Reviews Immunology [J]. Nat Rev Immunol，2011，11（10）：693-702.
[2] Marvel D，Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment：expect the unexpected [J]. J Clin Invest，2015，125（9）：3356-3364.
[3] Gabrilovich DI. Myeloid-Derived Suppressor Cells [J]. Cancer Immunol Res，2017，5（1）：3-8.
[4] Gabrilovich DI，Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system [J]. Nat Rev Immunol，2009，9（3）：162-174.
[5] Su Z，Ni P，Zhou C，et al. Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases：Angel or Demon? [J] Scand J Immunol，2016，84（5）：255-261.
[6] Solito S，Marigo I，Pinton L，et al. Myeloid-derived suppressor cell heterogeneity in human cancers [J]. Ann N Y Acad Sci，2014，1319：47-65.
[7] Kumar V，Patel S，Tcyganov E，et al. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment [J]. Trends Immunol，2016，37（3）：208-220.
[8] Ortiz ML，Lu L，Ramachandran I，et al. Myeloid-derived suppressor cells in the development of lung cancer [J]. Cancer Immunol Res，2014，2（1）：50-58.
[9] Wang L，Peng L，Dong B，et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer：association with a poor clinical outcome [J]. Ann Oncol，2006，17（10）：1517-1522.
[10] Li BH，Wang Y，Wang CY，et al. Up-Regulation of Phosphatase in Regenerating Liver-3 （PRL-3） Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten （PTEN）/Phosphoinositide 3-Kinase （PI3K）/AKT Signaling Pathway [J]. Med Sci Monit，2018， 24：8105-8114.
[11] Tamagawa H，Oshima T，Yoshihara K，et al. The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer [J]. Hepatogastroenterology，2012，59（119）：2122-2126.
[12] Wei M，Haney MG，Rivas DR，et al. Protein tyrosine phosphatase 4A3 （PTP4A3/PRL-3） drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo [J]. Oncogenesis，2020，9（1）：6.
[13] Zhou J，Toh SH，Chan ZL，et al. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/beta-catenin pathways for treatment of AML with high PRL-3 phosphatase [J]. J Hematol Oncol，2018，11（1）：36.
[14] Zhang C，Tian W，Meng L，et al. PRL-3 promotes gastric cancer migration and invasion through a NF-kappaB-HIF-1alpha-miR-210 axis [J]. J Mol Med （Berl），2016， 94（4）：401-415.
[15] Zhang M，Wei Y，Liu Y，et al. Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations [J]. iScience，2020，23（1）：100766.
[16] Xu J，Wu W，Tang Y，et al. PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling [J]. Aging（Albany NY），2019，11（18）：7817-7829.
[17] Tanaka T，Kaida T，Yokoi K，et al. Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer [J]. Oncol Lett，2019， 17（1）：1257-1266.
[18] Lian S，Meng L，Yang Y，et al. PRL-3 promotes telomere deprotection and chromosomal instability [J]. Nucleic Acids Res，2017，45（11）：6546-6571.
[19] Lv J，Liu C，Huang H，et al. Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3 [J]. Gene Ther，2013，20（8）：834-845.
[20] 王盛典，贾明明.肿瘤免疫微环境在肿瘤常规治疗效应中的作用[J].中国肿瘤生物治疗杂志，2012，19（3）：229-238.
[21] Miyazaki T，Ishikawa E，Sugii N，et al. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment [J]. Cancers（Basel），2020，12（7）.
[22] Looi CK，Chung FF，Leong CO，et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment [J]. J Exp Clin Cancer Res，2019，38（1）：162.
[23] Jacobs JF，Nierkens S，Figdor CG，et al. Regulatory T cells in melanoma： the final hurdle towards effective immunotherapy? [J] Lancet Oncol，2012，13（1）：e32-42.
[24] Predina J，Eruslanov E，Judy B，et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery [J]. Proc Natl Acad Sci USA，2013，110（5）：E415-E424.
[25] Dang Y，Wagner WM，Gad E，et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells [J]. Clin Cancer Res，2012， 18（11）：3122-3131.
[26] Rabinovich GA，Gabrilovich D，Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells [J]. Annu Rev Immuno，2007，25：267-296.
[27] Xu M，Du X，Liu M，et al. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody [J]. Protein Cell，2012，3（6）：441-449.
[28] Kirkwood JM，Butterfield LH，Tarhini AA，et al. Immunotherapy of cancer in 2012 [J]. CA Cancer J Clin，2012，62（5）：309-335. |
|
|
|
